Extracellular Matrix Degradation Products Downregulate Neoplastic Esophageal Cell Phenotype.

Journal Article (Journal Article)

Impact statement

Extracellular matrix (ECM) biomaterials were used to treat esophageal cancer patients after cancer resection and promoted regrowth of normal mucosa without recurrence of cancer. The present study investigates the mechanisms by which these materials were successful to prevent the cancerous phenotype. ECM downregulated neoplastic esophageal cell function (proliferation, metabolism), but normal esophageal epithelial cells were unaffected in vitro , and suggests a molecular basis (downregulation of PI3K-Akt, cell cycle) for the promising clinical results. The therapeutic effect appeared to be enhanced using homologous esophageal ECM. This study suggests that ECM can be further investigated to treat cancer patients after resection or in combination with targeted therapy.

Full Text

Duke Authors

Cited Authors

  • Saldin, LT; Patel, S; Zhang, L; Huleihel, L; Hussey, GS; Nascari, DG; Quijano, LM; Li, X; Raghu, D; Bajwa, AK; Smith, NG; Chung, CC; Omstead, AN; Kosovec, JE; Jobe, BA; Turner, NJ; Zaidi, AH; Badylak, SF

Published Date

  • March 2019

Published In

Volume / Issue

  • 25 / 5-6

Start / End Page

  • 487 - 498

PubMed ID

  • 30259795

Pubmed Central ID

  • PMC6450457

Electronic International Standard Serial Number (EISSN)

  • 1937-335X

International Standard Serial Number (ISSN)

  • 1937-3341

Digital Object Identifier (DOI)

  • 10.1089/ten.tea.2018.0105


  • eng